Annexon appoints Jamie Dananberg as CMO; ARCHER trial shows ANX007 vision protection in GA

Annexon, Inc.

Jamie Dananberg, M.D., appointed chief medical officer; previously CMO at UNITY Biotechnology and exec at Takeda and Eli Lilly.
ARCHER Phase 2 trial in geographic atrophy showed ANX007 provided dose-dependent, statistically significant protection from vision loss (BCVA ≥15 letters).
Primary endpoint of GA lesion growth rate did not reach significance; additional analyses show trend toward greater effect in second six months.
ANX007 was well-tolerated with no increase in CNV or retinal vasculitis; company to discuss regulatory path with FDA later this year.
Fellow-eye analysis showed 74% (monthly) and 47% (every-other-month) reduction in BCVA loss vs sham; off-treatment data support on-treatment benefit.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.